Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer
about
Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastasesCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapyFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentPhase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancerCytohesins/ARNO: the function in colorectal cancer cellsNew insights into the molecular pathogenesis of colorectal cancer.Selection and characterization of cell binding and internalizing phage antibodies.Exploiting novel molecular targets in gastrointestinal cancers.Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.Targeting the tumor microenvironment: focus on angiogenesis.Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsFolliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.Cellular responses to EGFR inhibitors and their relevance to cancer therapy.Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study.A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).Targeted therapies in colorectal cancer-an integrative view by PPPMEpidermal growth factor receptor as a major anticancer drug target.Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.EGFR targeting of solid tumors.Predictive and prognostic markers in colorectal cancer.Combined anti-proliferative and anti-angiogenic strategies for cancer.Clinical biomarkers of angiogenesis inhibition.Future of targeted agents in metastatic colorectal cancer.New treatment options for advanced pancreatic cancer.Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.Colorectal cancer in review: the role of the EGFR pathway.Polarization of macrophages in the tumor microenvironment is influenced by EGFR signaling within colon cancer cellsPrecise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes.Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agentsOptimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.Mechanisms of receptor tyrosine kinase activation in cancer.CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
P2860
Q26772274-20CB7789-770F-45C5-B0F6-D10EE4ED72FBQ26859144-0BF87167-E967-478F-A63B-E57CF0DEFA19Q26993238-0D5B9197-6562-48CD-8F03-7735DC795D78Q28533949-73D6571B-E57E-4A22-9F3E-5341639DE830Q28534997-F90588F7-26CC-468D-A97E-A2B3ED0B5B4EQ28540770-28926968-9C5C-4C0E-834C-C6B3D51EDA8CQ33640592-2F2A3478-BDCD-4447-9F01-E71ABF1FF078Q34280931-915EE595-5773-4E70-AC67-4CD6043BAEB7Q34382777-C06D1F3F-B8D0-4913-9A90-FA8A6CD1B3FDQ34404779-B85FBF71-E9B1-4F0D-B049-D4E5B5E9A616Q35055207-3D091A73-9932-4E95-B933-46F9A5249617Q35184806-8AE76785-C0E0-40A9-A8A1-0E8FFEAFD88FQ35263024-1B5DC880-EF3F-41E0-B896-72CB02EF0603Q35652789-EA878747-14AD-4DA4-A3C1-E98F4166B3ACQ35913241-07F44C7F-7803-4DB8-8168-3C457BB356E3Q36003118-453CF64D-F3F8-4BB2-9550-5FFCC22B5C42Q36175239-AB423D5E-E7D9-4FB1-AF5E-EAA082C37319Q36452865-1E03D8E0-9D42-44C5-B702-0F7C6E85AA1DQ36484566-B6742C9B-38EE-499C-B5BB-14E5889DA8B4Q36646911-666CDDE3-2E7B-459A-97B0-0A096A47F9E6Q36653667-1187EEF8-4853-43CE-AE69-535EE7644C9DQ36788485-BFB6C943-D8DA-40C7-B0DD-2EBAF61BF599Q36793661-1A470C7B-B346-4736-9621-0409FF499B1CQ36862836-6E10C0D5-1917-45C8-ACF1-639C75B0A4DFQ36872290-D5ED9579-A130-46F6-8943-136104954610Q37073444-7B3C3E05-8B70-4D04-BA36-B818818F21ABQ37111832-A7CE1EA6-F925-45DD-94A8-3095E6AA3B3BQ37139413-E7C7BDDB-C246-4D58-8C5F-C3412A6DB067Q37326863-5A651653-AD02-4325-AEAD-FCFC736AB93AQ37345841-C7691414-0D67-4F83-8108-E4477037E57EQ37618803-657357BD-2F17-4079-B21B-900CF01ECBABQ37679938-BBBC208B-7BE8-4CA3-BD2A-C37AD7CC9720Q37688949-F7C5034E-6B07-4804-A99E-417529A18C82Q37702015-C3489FD4-EE48-4FB0-9D60-0ACFDE717BCFQ37861547-1919EEC4-EF6F-416F-B681-964212B362F4Q38071119-1EF54F16-194C-4958-843D-A2279DBC6B0BQ38661133-8B2DD995-99AD-4828-A5F1-500F6EF1A107Q45974732-EE2D8247-0572-4D3E-8292-A6F3C40E2B5EQ49888000-04F1862F-F2FD-4C9C-9C8E-B6A7303576CBQ50607666-91368525-F148-4193-B673-A509DD22FBE2
P2860
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Randomized phase III trial res ...... n metastatic colorectal cancer
@ast
Randomized phase III trial res ...... n metastatic colorectal cancer
@en
Randomized phase III trial res ...... n metastatic colorectal cancer
@nl
type
label
Randomized phase III trial res ...... n metastatic colorectal cancer
@ast
Randomized phase III trial res ...... n metastatic colorectal cancer
@en
Randomized phase III trial res ...... n metastatic colorectal cancer
@nl
prefLabel
Randomized phase III trial res ...... n metastatic colorectal cancer
@ast
Randomized phase III trial res ...... n metastatic colorectal cancer
@en
Randomized phase III trial res ...... n metastatic colorectal cancer
@nl
P2093
P921
P356
P1476
Randomized phase III trial res ...... n metastatic colorectal cancer
@en
P2093
Aarati Ranganathan
Axel Grothey
Tara Beers Gibson
P356
10.3816/CCC.2006.N.01
P407
P577
2006-05-01T00:00:00Z